These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 2515963

  • 1. Antibacterial and plasmid curing activity of lomefloxacin in vitro.
    Derlot E, Poyart-Salmeron C, Courvalin P.
    Eur J Clin Microbiol Infect Dis; 1989 Dec; 8(12):1048-52. PubMed ID: 2515963
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of in vitro antimicrobial activity of lomefloxacin against staphylococci, enterococci, Enterobacteriaceae, and Pseudomonas aeruginosa.
    Rossolini GM, Valentini S, Satta G.
    Diagn Microbiol Infect Dis; 1989 Dec; 12(3 Suppl):57S-64S. PubMed ID: 2507221
    [Abstract] [Full Text] [Related]

  • 3. Antibacterial activity of lomefloxacin in a pharmacokinetic in vitro model.
    Rustige C, Wiedemann B.
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1107-11. PubMed ID: 2118324
    [Abstract] [Full Text] [Related]

  • 4. In-vitro activity of lomefloxacin in comparison with pefloxacin and ofloxacin.
    Van der Auwera P, Grenier P, Glupczynski Y, Pierard D.
    J Antimicrob Chemother; 1989 Feb; 23(2):209-19. PubMed ID: 2496071
    [Abstract] [Full Text] [Related]

  • 5. Antibacterial activity of lomefloxacin.
    Leigh DA, Tait S, Walsh B.
    J Antimicrob Chemother; 1991 May; 27(5):589-98. PubMed ID: 1885417
    [Abstract] [Full Text] [Related]

  • 6. In vitro activity of lomefloxacin against multiply resistant Pseudomonas aeruginosa, Enterobacter cloacae, and Staphylococcus epidermidis.
    DiVincenzo CA, Shatzer KL, Venezio FR.
    Diagn Microbiol Infect Dis; 1989 May; 12(3 Suppl):13S-16S. PubMed ID: 2507220
    [Abstract] [Full Text] [Related]

  • 7. In vitro activity of lomefloxacin (NY-198 or SC 47111).
    Shah PM, Müller S, Kipp J, Stille W.
    Diagn Microbiol Infect Dis; 1989 May; 12(3 Suppl):97S-101S. PubMed ID: 2791506
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Correlation of in vitro activities of the fluoroquinolones to their in vivo efficacies.
    Fernandes PB, Swanson RN.
    Drugs Exp Clin Res; 1988 May; 14(6):375-8. PubMed ID: 3145851
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. In-vitro activity of lomefloxacin (SC-47111) and other quinolones.
    Sun ZM, Maskell JP, Sehgal SC, Williams JD.
    Infection; 1989 May; 17(3):165-7. PubMed ID: 2737760
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. In vitro evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
    Stamm JM, Hanson CW, Chu DT, Bailer R, Vojtko C, Fernandes PB.
    Antimicrob Agents Chemother; 1986 Feb; 29(2):193-200. PubMed ID: 3087274
    [Abstract] [Full Text] [Related]

  • 20. Lomefloxacin-induced modification of the kinetics of growth of gram-negative bacteria and susceptibility to phagocytic killing by human neutrophils.
    Pruul H, McDonald PJ.
    J Antimicrob Chemother; 1990 Jan; 25(1):91-101. PubMed ID: 2108116
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.